Overweight and Obesity
Conditions
Brief summary
This protocol will determine the pK profile of two different omega-3 fatty acid supplements on plasma EPA and DHA levels.
Detailed description
This protocol is to assess the omega-3 blood levels of DHA and EPA following a single dose administration of study products by means of pharmacokinetics over a 24 hour period of time (post-dose).
Interventions
DIETARY_SUPPLEMENTOM3-supplement 1
1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
DIETARY_SUPPLEMENTOM3-supplement 2
1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
Sponsors
Miami Research Associates
Société des Produits Nestlé (SPN)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female subjects between 18 and 65 years old (inclusive) 2. Body Mass Index (BMI) between 25.0 and 34.9 kg/m2 (inclusive) at Screening. 3. Subjects with normal or moderately elevated lipidemia (borderline lipids as defined by the AACE - Total cholesterol ≤ 240 mg/dl; LDL ≤ 160 mg/dl; TG ≤ 199 mg/dl). 4. Subjects with no clinically significant findings in the physical examination, medical history, vital signs, clinical laboratory test (hematology and serum chemistry) results and as deemed by the Investigator. 5. Subjects must understand and agree to comply with the requirements of the study and they must be willing to sign the informed consent indicating voluntary consent to participate in the study prior to the initiation of Screening or study related activities. 6. Male and female subjects of childbearing potential must agree to use one of the following medically acceptable contraceptive methods for the duration of the study: same-sex partner; double barrier (condom, diaphragm or cervical cap with spermicidal foam, gel or cream); IUD (with or without hormones) in place or hormonal contraception (oral, injectable, implantable, transdermal or vaginal) used consecutively for at least 3 months prior to study product administration; vasectomized partner or sterilization by bilateral insertion of Essure® or similar product for 6 months minimum prior to study product administration; bilateral tubal ligation, hysterectomy and/or bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to study product administration
Exclusion criteria
1. Currently using fish oil capsules (supplements or prescription products). 2. Regular use of omega-3 supplements (defined as greater than 500 mg/week) within 4 weeks of study product administration. 3. Currently using any medications that may impact dietary fat absorption (i.e., Orlistat, Alli, etc.). 4. Currently using any medications that may interfere with omega-3 uptake (i.e. blood thinning medication or anticoagulants). 5. Currently using any lipid lowering medications (i.e. any cholesterol or triglyceride lowering agent). 6. Currently consuming high amounts of EPA & DHA in the diet (as defined by greater than 200 mg/day by FFQ) 7. Currently following a self-reported no-fat or ultra-restrictive (less than 15%) Low-Fat Diet 8. Having the following medical conditions: i. Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease, etc. ii. Hypertriglyceridemia (as defined by the Inclusion and per PI discretion; Total cholesterol \> 240 mg/dl; LDL \> 160 mg/dl; TG \> 199 mg/dl) iii. Type2 Diabetes Mellitus 9. Currently a smoker or nicotine user or has been nicotine free for less than 6 months 10. Use of any systemic medications, including OTC medications, herbal products, dietary supplements or vitamins (not previously listed) within 1 week of study product administration (occasional use of OTC analgesics such as acetaminophen may be allowed as judged by the Investigator) 11. Evidence or history of allergic or adverse responses to either study product, any of the product excipients or any comparable or similar products 12. Subjects who are not willing and not able to comply with scheduled visits and the requirements of the study protocol. 13. Female subjects who are breastfeeding, pregnant or plan to become pregnant during this study. 14. Current employee or immediate family member of the study sponsor or study site personnel. 15. Currently participating or have participated in another clinical trial within 4 weeks of study product administration 16. Donated blood, blood components, or significant loss of blood within 30 days of study product administration 17. History of a clinically-significant illness within 4 weeks of study product administration 18. History of hospitalization or treatment for clinically-significant drug or alcohol use/abuse within 1 year of dosing. 19. Subject has poor venous access or difficulty swallowing capsules 20. Any other issue which, in the judgment of the Investigator, will make the subject ineligible for study participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-t | from 0 to 24 hours | The plasma pharmacokinetics (AUC0-t) resulting from a single oral dose administration will be estimated from 0 to 24 hours post-dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-inf | from 0 to infinity | The plasma pharmacokinetics (AUC0-t) resulting from a single oral dose administration will be estimated from o to infinity |
| Cmax | between 0 and 24 hours | The plasma pharmacokinetics (Cmax) resulting from a single oral dose administration will be estimated from 0 to 24 hours post-dose |
| tmax | between 0 and 24 hours | The plasma pharmacokinetics (tmax) resulting from a single oral dose administration will be estimated from 0 to 24 hours post-dose |
| t½ | between 0 and 24 hours | The plasma pharmacokinetics (t1/2) resulting from a single oral dose administration will be estimated from 0 to 24 hours post-dose |
Countries
United States
Outcome results
None listed